Literature DB >> 29933504

Unique Variant of NOD2 Pediatric Granulomatous Arthritis With Severe 1,25-Dihydroxyvitamin D-Mediated Hypercalcemia and Generalized Osteosclerosis.

Michael P Whyte1,2, Emilina Lim3, William H McAlister4, Gary S Gottesman1, Lien Trinh5, Deborah J Veis6, Vinieth N Bijanki1, Matthew G Boden1, Angela Nenninger1, Steven Mumm1,2, David Buchbinder7.   

Abstract

Pediatric granulomatous arthritis (PGA) refers to two formerly separate entities: autosomal dominant Blau syndrome (BS) and its sporadic phenocopy early-onset sarcoidosis (EOS). In 2001 BS and in 2005 EOS became explained by heterozygous mutations within the gene that encodes nucleotide-binding oligomerization domain-containing protein 2 (NOD2), also called caspase recruitment domain-containing protein 15 (CARD15). NOD2 is a microbe sensor in leukocyte cytosol that activates and regulates inflammation. PGA is characterized by a triad of autoinflammatory problems (dermatitis, uveitis, and arthritis) in early childhood, which suggests the causal NOD2/CARD15 mutations are activating defects. Additional complications of PGA were recognized especially when NOD2 mutation analysis became generally available. However, in PGA, hypercalcemia is only briefly mentioned, and generalized osteosclerosis is not reported, although NOD2 regulates NF-κB signaling essential for osteoclastogenesis and osteoclast function. Herein, we report a 4-year-old girl with PGA uniquely complicated by severe 1,25(OH)2 D-mediated hypercalcemia, nephrocalcinosis, and compromised renal function together with radiological and histopathological features of osteopetrosis (OPT). The classic triad of PGA complications was absent, although joint pain and an antalgic gait accompanied wrist, knee, and ankle swelling and soft non-tender masses over her hands, knees, and feet. MRI revealed tenosynovitis in her hands and suprapatellar effusions. Synovial biopsy demonstrated reactive synovitis without granulomas. Spontaneous resolution of metaphyseal osteosclerosis occurred while biochemical markers indicated active bone turnover. Anti-inflammatory medications suppressed circulating 1,25(OH)2 D, corrected the hypercalcemia, and improved her renal function, joint pain and swelling, and gait. Mutation analysis excluded idiopathic infantile hypercalcemia, type 1, and known forms of OPT, and identified a heterozygous germline missense mutation in NOD2 common in PGA (c.1001G>A, p.Arg334Gln). Thus, radiological and histological findings of OPT and severe hypercalcemia from apparent extrarenal production of 1,25(OH)2 D can complicate NOD2-associated PGA. Although the skeletal findings seem inconsequential, treatment of the hypercalcemia is crucial to protect the kidneys.
© 2018 American Society for Bone and Mineral Research. © 2018 American Society for Bone and Mineral Research.

Entities:  

Keywords:  ARTHRITIS; AUTOINFLAMMATION; BLAU SYNDROME; CARD15; DERMATITIS; GLUCOCORTICOIDS; GRANULOMA; GRANULOMATOUS DISEASE; HYPERCALCIURIA; METHOTREXATE; NEOPTERIN; NEPHROCALCINOSIS; NEPHROPATHY; NF-κB; NOD2; OSTEOBLAST; OSTEOCLAST; OSTEOPETROSIS; OSTEOSCLEROSIS; SARCOIDOSIS; SYNOVITIS; UVEITIS; VITAMIN D

Mesh:

Substances:

Year:  2018        PMID: 29933504      PMCID: PMC6636828          DOI: 10.1002/jbmr.3532

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  43 in total

1.  Neonatal High Bone Mass With First Mutation of the NF-κB Complex: Heterozygous De Novo Missense (p.Asp512Ser) RELA (Rela/p65).

Authors:  Anja L Frederiksen; Martin J Larsen; Klaus Brusgaard; Deborah V Novack; Peter Juel Thiis Knudsen; Henrik Daa Schrøder; Weimin Qiu; Christina Eckhardt; William H McAlister; Moustapha Kassem; Steven Mumm; Morten Frost; Michael P Whyte
Journal:  J Bone Miner Res       Date:  2015-08-06       Impact factor: 6.741

2.  Childhood sarcoidosis: Louisiana experience.

Authors:  Abraham Gedalia; Tahir A Khan; Avinash K Shetty; Victoria R Dimitriades; Luis R Espinoza
Journal:  Clin Rheumatol       Date:  2015-01-24       Impact factor: 2.980

3.  Long-term treatment of osteopetrosis with recombinant human interferon gamma.

Authors:  L L Key; R M Rodriguiz; S M Willi; N M Wright; H C Hatcher; D R Eyre; J K Cure; P P Griffin; W L Ries
Journal:  N Engl J Med       Date:  1995-06-15       Impact factor: 91.245

4.  Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with Blau syndrome.

Authors:  Nobuo Kanazawa; Ikuo Okafuji; Naotomo Kambe; Ryuta Nishikomori; Mami Nakata-Hizume; Sonoko Nagai; Akihiko Fuji; Takenosuke Yuasa; Akira Manki; Yoshihiko Sakurai; Mitsuru Nakajima; Hiroko Kobayashi; Ikuma Fujiwara; Hiroyuki Tsutsumi; Atsushi Utani; Chikako Nishigori; Toshio Heike; Tatsutoshi Nakahata; Yoshiki Miyachi
Journal:  Blood       Date:  2004-09-30       Impact factor: 22.113

5.  Elevated serum lactate dehydrogenase isoenzymes and aspartate transaminase distinguish Albers-Schönberg disease (Chloride Channel 7 Deficiency Osteopetrosis) among the sclerosing bone disorders.

Authors:  Michael P Whyte; Lydia G Kempa; William H McAlister; Fan Zhang; Steven Mumm; Deborah Wenkert
Journal:  J Bone Miner Res       Date:  2010-11       Impact factor: 6.741

6.  Regulatory regions and critical residues of NOD2 involved in muramyl dipeptide recognition.

Authors:  Tsuyoshi Tanabe; Mathias Chamaillard; Yasunori Ogura; Li Zhu; Su Qiu; Junya Masumoto; Partho Ghosh; Anthony Moran; Martina M Predergast; Gerard Tromp; Charlene J Williams; Naohiro Inohara; Gabriel Núñez
Journal:  EMBO J       Date:  2004-03-25       Impact factor: 11.598

7.  Mutational analysis of human NOD1 and NOD2 NACHT domains reveals different modes of activation.

Authors:  Birte Zurek; Martina Proell; Roland N Wagner; Robert Schwarzenbacher; Thomas A Kufer
Journal:  Innate Immun       Date:  2011-02-10       Impact factor: 2.680

Review 8.  Dysosteosclerosis presents as an "osteoclast-poor" form of osteopetrosis: comprehensive investigation of a 3-year-old girl and literature review.

Authors:  Michael P Whyte; Deborah Wenkert; William H McAlister; Deborah V Novack; Angie R Nenninger; Xiafang Zhang; Margaret Huskey; Steven Mumm
Journal:  J Bone Miner Res       Date:  2010-11       Impact factor: 6.741

Review 9.  Insights into the molecular basis of the NOD2 signalling pathway.

Authors:  Joseph P Boyle; Rhiannon Parkhouse; Tom P Monie
Journal:  Open Biol       Date:  2014-12       Impact factor: 6.411

Review 10.  Blau syndrome, the prototypic auto-inflammatory granulomatous disease.

Authors:  Carine H Wouters; Anne Maes; Kevin P Foley; John Bertin; Carlos D Rose
Journal:  Pediatr Rheumatol Online J       Date:  2014-08-06       Impact factor: 3.054

View more
  2 in total

Review 1.  Distinguishing Blau Syndrome from Systemic Sarcoidosis.

Authors:  Katherine P Kaufman; Mara L Becker
Journal:  Curr Allergy Asthma Rep       Date:  2021-02-09       Impact factor: 4.806

2.  Effective treatment of TNFα inhibitors in Chinese patients with Blau syndrome.

Authors:  Jing Chen; Yi Luo; Mengzhu Zhao; Di Wu; Yunjiao Yang; Wen Zhang; Min Shen
Journal:  Arthritis Res Ther       Date:  2019-11-12       Impact factor: 5.156

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.